Figure 2
![Figure 2. Flow cytometry figure comparing B-cell populations in a healthy volunteer (Ctrl), and in a patient with HCV-MC vasculitis before (MC pre-Rx) and after (at month +1 [MC post-Rx M1] and at month +12 [MC post-Rx M12]) rituximab.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/111/11/10.1182_blood-2007-11-122713/6/zh80090818790002.jpeg?Expires=1735839879&Signature=bCziHuAIZsxAXC9AlhkBXGHSmk46pzusTVThB54m1c9OsbV8P8gXWl91yrsozpT9zw7Yu66LblbxNYzm3t1yZBW5er9PlmZBpWyztIkNTG1udiN9Uf6Zpk1~v3BnokJ8SLsf9ueZ~5Vr-6LCrnvcCkDpfnwSXPN7RpGs3gLF-KlDcLmPanzYSaCVFYDNpI7oCzNp1qjI9lOBnCGvr3H33qoml2kEwY2XIJlChNCMEvrsBrUxqbA9CyDJ3BefPnKkXIuN63wBwFqPxqN6pMe0WD4UxDJB33gdPjD1VkuLLslrOSe6jf0zVtlNz9wbBf5Z7DLPybgmXDRgxbLi-dEMKg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Flow cytometry figure comparing B-cell populations in a healthy volunteer (Ctrl), and in a patient with HCV-MC vasculitis before (MC pre-Rx) and after (at month +1 [MC post-Rx M1] and at month +12 [MC post-Rx M12]) rituximab.
Flow cytometry figure comparing B-cell populations in a healthy volunteer (Ctrl), and in a patient with HCV-MC vasculitis before (MC pre-Rx) and after (at month +1 [MC post-Rx M1] and at month +12 [MC post-Rx M12]) rituximab.
